Bluebird Lenti-D Data Give Gene Therapy Business Another Boost

Results Show Continued Positive Safety, Efficacy Profile

Gene therapy
Bluebird announced positive follow-up data for Lenti-D in cerebral adrenoleukodystrophy. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Neurological

More from Therapy Areas